IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis | Zendy

Zoe Kane | Zendy; Silke Gastine | Zendy; Christina W. Obiero | Zendy; Phoebe Williams | Zendy; Sheila Murunga | Zendy; Johnstone Thitiri | Zendy; Sally Ellis | Zendy; Erika Correia | Zendy; Boryaoke | Zendy; Karin Kipper | Zendy; John van den Anker | Zendy; Mike Sharland | Zendy; James A. Berkley | Zendy; Joseph F. Standing | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

IV and oral fosfomycin pharmacokinetics in neonates with suspected clinical sepsis

Author(s) -

Zoe Kane,

Silke Gastine,

Christina W. Obiero,

Phoebe Williams,

Sheila Murunga,

Johnstone Thitiri,

Sally Ellis,

Erika Correia,

Boryaoke,

Karin Kipper,

John van den Anker,

Mike Sharland,

James A. Berkley,

Joseph F. Standing

Publication year - 2021

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkab083

Subject(s) - fosfomycin , pharmacokinetics , medicine , sepsis , intensive care medicine , antibiotics , microbiology and biotechnology , biology

Fosfomycin has the potential to be re-purposed as part of a combination therapy to treat neonatal sepsis where resistance to current standard of care (SOC) is common. Limited data exist on neonatal fosfomycin pharmacokinetics and estimates of bioavailability and CSF/plasma ratio in this vulnerable population are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research